Resveratrol attenuates lipopolysaccharide-induced acute kidney injury by suppressing inflammation driven by macrophages

Molecular Nutrition and Food Research

Volumn 59, Issue 5, 2015, Pages 853-864

  Chen, Liang ^a   Yang, Sixing ^a   Zumbrun, Elizabeth E ^b   Guan, Hongbing ^b   Nagarkatti, Prakash S ^b   Nagarkatti, Mitzi ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

AKI; Kidney injury; LPS; Macrophage; Resveratrol

Indexed keywords

BACTERIA (MICROORGANISMS); MUS;

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; RESVERATROL; STILBENE DERIVATIVE; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ACUTE KIDNEY INJURY; ANIMAL; APOPTOSIS; C57BL MOUSE; CAPILLARY PERMEABILITY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; INFLAMMATION; KIDNEY; MACROPHAGE; MOUSE; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; CAPILLARY PERMEABILITY; FEMALE; INFLAMMATION; KIDNEY; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED C57BL; NF-KAPPA B; SIGNAL TRANSDUCTION; STILBENES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928656747     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400819     Document Type: Article

References (44)

1. Cohen, J., The immunopathogenesis of sepsis. Nature 2002, 420, 885-891.
2. Zarjou, A., Agarwal, A., Sepsis and acute kidney injury. J. Am. Soc. Nephrol. 2011, 22, 999-1006.
3. Rivers, E. P., Coba, V., Whitmill, M., Early goal-directed therapy in severe sepsis and septic shock: a contemporary review of the literature. Curr. Opin. Anaesthesiol. 2008, 21, 128-140.
4. Otero, R. M., Nguyen, H. B., Huang, D. T., Gaieski, D. F. et al., Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings. Chest 2006, 130, 1579-1595.
5. Langenberg, C., Wan, L., Egi, M., May, C. N. et al., Renal blood flow in experimental septic acute renal failure. Kidney International 2006, 69, 1996-2002.
6. Wan, L., Bagshaw, S. M., Langenberg, C., Saotome, T. et al., Pathophysiology of septic acute kidney injury: what do we really know? Crit. Care Med. 2008, 36, S198-S203.
7. Chvojka, J., Sykora, R., Karvunidis, T., Radej, J. et al., New developments in septic acute kidney injury. Physiol. Res. 2010, 59, 859-869.
8. Legrand, M., Bezemer, R., Kandil, A., Demirci, C. et al., The role of renal hypoperfusion in development of renal microcirculatory dysfunction in endotoxemic rats. Intens. Care Med. 2011, 37, 1534-1542.
9. Doi, K., Leelahavanichkul, A., Yuen, P. S., Star, R. A., Animal models of sepsis and sepsis-induced kidney injury. J. Clin. Invest. 2009, 119, 2868-2878.
10. Lech, M., Anders, H. J., Macrophages and fibrosis: how resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. Biochim. Biophys. Acta 2013, 1832, 989-997.
11. Nelson, P. J., Rees, A. J., Griffin, M. D., Hughes, J. et al., The renal mononuclear phagocytic system. J. Am. Soc. Nephrol. 2012, 23, 194-203.
12. Griffin, M. D., Mononuclear phagocyte depletion strategies in models of acute kidney disease: what are they trying to tell us? Kidney Int. 2012, 82, 835-837.
13. Alagesan, S., Griffin, M. D., Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor. Kidney Int. 2014, 85, 730-733.
14. El-Achkar, T. M., Hosein, M., Dagher, P. C., Pathways of renal injury in systemic Gram-negative sepsis. Eur. J. Clin. Invest. 2008, 38(Suppl 2), 39-44.
15. Verstrepen, L., Bekaert, T., Chau, T. L., Tavernier, J. et al., TLR-4, IL-1R and TNF-R signaling to NF-kappa B: variations on a common theme. Cell. Mol. Life Sci. 2008, 65, 2964-2978.
16. Mayeux, P. R., MacMillan-Crow, L. A., Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury. Pharmacol. Ther. 2012, 134, 139-155.
17. Hong, S., Lu, Y., Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury. Front. Immunol. 2013, 4, 13.
18. Baur, J. A., Sinclair, D. A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493-506.
19. Rieder, S. A., Nagarkatti, P., Nagarkatti, M., Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury. Br. J. Pharmacol. 2012, 167, 1244-1258.
20. Holthoff, J. H., Wang, Z., Seely, K. A., Gokden, N. et al., Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int. 2012, 81, 370-378.
21. Kitada, M., Koya, D., Renal protective effects of resveratrol. Oxid. Med. Cell. Longev. 2013, 2013, 568093.
22. Jakus, P. B., Kalman, N., Antus, C., Radnai, B. et al., TRAF6 is functional in inhibition of TLR4-mediated NF-kappa B activation by resveratrol. J. Nutr. Biochem. 2013, 24, 819-823.
23. Yang, Y., Li, S., Yang, Q., Shi, Y. et al., Resveratrol reduces the proinflammatory effects and lipopolysaccharide-induced expression of HMGB1 and TLR4 in RAW264.7 cells. Cell. Physiol. Biochem. 2014, 33, 1283-1292.
24. Mustafa, A., McKallip, R. J., Fisher, M., Duncan, R. et al., Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. J. Immunother. 2002, 25, 476-488.
25. Akcay, A., Nguyen, Q., Edelstein, C. L., Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009, 2009, 137072.
26. Flad, H. D., Grage-Griebenow, E., Petersen, F., Scheuerer, B. et al., The role of cytokines in monocyte apoptosis. Pathobiology 1999, 67, 291-293.
27. Akira, S., Uematsu, S., Takeuchi, O., Pathogen recognition and innate immunity. Cell 2006, 124, 783-801.
28. Lombardo, E., Alvarez-Barrientos, A., Maroto, B., Bosca, L. et al., TLR4-mediated survival of macrophages is MyD88 dependent and requires TNF-alpha autocrine signalling. J. Immunol. 2007, 178, 3731-3739.
29. Dudley, C., Maximizing renal preservation in acute renal failure. BJU Int. 2004, 94, 1202-1206.
30. Nguyen, H. B., Corbett, S. W., Menes, K., Cho, T. et al., Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department. Acad. Emerg. Med. 2006, 13, 109-113.
31. El-Achkar, T. M., Huang, X., Plotkin, Z., Sandoval, R. M. et al., Sepsis induces changes in the expression and distribution of Toll-like receptor 4 in the rat kidney. Am. J. Physiol. Renal Physiol. 2006, 290, F1034-F1043.
32. Palsamy, P., Subramanian, S., Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim. Biophys. Acta 2011, 1812, 719-731.
33. Shi, Y. W., Wang, C. P., Liu, L., Liu, Y. L. et al., Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. Mol. Nutr. Food Res. 2012, 56, 1433-1444.
34. Benes, J., Chvojka, J., Sykora, R., Radej, J. et al., Searching for mechanisms that matter in early septic acute kidney injury: an experimental study. Crit. Care 2011, 15, R256.
35. Holly, M. K., Dear, J. W., Hu, X., Schechter, A. N. et al., Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney Int. 2006, 70, 496-506.
36. Sutton, T. A., Dagher, P. C., Fueling the fire in acute kidney injury: endothelial cells collect their Toll. Kidney Int. 2011, 79, 267-269.
37. Kim, D. H., Jung, Y. J., Lee, A. S., Lee, S. et al., COMP-angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury. Kidney Int. 2009, 76, 1180-1191.
38. Ergin, B., Kapucu, A., Demirci-Tansel, C., Ince, C., The renal microcirculation in sepsis. Nephrol. Dial. Transpl. 2015, 30, 169-177.
39. Lee, S., Huen, S., Nishio, H., Nishio, S. et al., Distinct macrophage phenotypes contribute to kidney injury and repair. J. Am. Soc. Nephrol. 2011, 22, 317-326.
40. Xu, C., Chang, A., Hack, B. K., Eadon, M. T. et al., TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis. Kidney Int. 2014, 85, 72-81.
41. Misseri, R., Meldrum, D. R., Dinarello, C. A., Dagher, P. et al., TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am. J. Physiol. Renal Physiol. 2005, 288, F406-F411.
42. Anders, H. J., Ryu, M., Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 2011, 80, 915-925.
43. Ricardo, S. D., vanGoor, H., Eddy, A. A., Macrophage diversity in renal injury and repair. J. Clin. Invest. 2008, 118, 3522-3530.
44. Duffield, J. S., Macrophages and immunologic inflammation of the kidney. Semin. Nephrol. 2010, 30, 234-254.